Skip to main content
SpringerLink
Log in

Risk-Benefit Assessment of Omeprazole in the Treatment of Gastrointestinal Disorders

  • Review Article
  • Risk-Benefit Assessment
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

For the treatment of duodenal and gastric ulcer and reflux oesophagitis, especially erosive oesophagitis, omeprazole has an advantage over histamine H2-receptor antagonists because it heals significantly more patients significantly faster. Adverse effects have been observed during short term treatment with the same frequency as during treatment with H2-antagonists.

Also, maintenance treatment with omeprazole of reflux oesophagitis is significantly superior to H2-antagonist therapy. During long term treatment for up to 8 years no further drug-related adverse effects have been observed. Moderate hypergastrinaemia occurs in some patients, especially if an omeprazole dosage of 40 mg/day is needed.

A slight increase of the agyrophil (endocrine) cell volume density and an extension of micronodular hyperplasia in the oxyntic mucosa after several years of omeprazole treatment seem to be related to the severity of the corpus gastritis and not to drug-induced hypergastrinaemia, because similar changes have been observed in equal frequency in patients not receiving antisecretory drugs.

Theoretical arguments against long term treatment with potent acid-suppressing drugs, such as the possible consequences of gastric bacterial overgrowth or hypergastrinaemia, are not supported by clinical observations and epidemiological data and are, therefore, speculative.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Andersson T. Omeprazole drug interaction studies. Clinical Pharmacokinetics 21: 195–212, 1991

    PubMed  CAS  Google Scholar 

  • Andersson T, Andrén K, Cederberg C, Edvardsson G, Heggelund A, et al. Effect of omeprazole and Cimetidine on plasma diazepam levels. European Journal of Clinical Pharmacology 39: 51–54, 1990a

    PubMed  CAS  Google Scholar 

  • Andersson T, Bergstrand R, Cederberg C, Eriksson S, Lagerström PO, et al. Omeprazole treatment does not affect the metabolism of caffeine. Gastroenterology 101: 943–947, 1991a

    PubMed  CAS  Google Scholar 

  • Andersson T, Cederberg C, Heggelund A, Lundborg P. The pharmacokinetics of single and repeated once daily doses of 10, 20 and 40mg omeprazole as enteric coated granules. Drug Investigation 3: 45–52, 1991b

    Google Scholar 

  • Andersson T, Cederberg C, Regardh CG, Skänberg I. Pharmacogenics of various single intravenous and oral doses of omeprazole. European Journal of Clinical Pharmacology 39: 195–197, 1990b

    PubMed  CAS  Google Scholar 

  • Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl ML, et al. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2: 25–31, 1992

    PubMed  CAS  Google Scholar 

  • Arens MJ, Dent J. Acid pump blockers: what are their current therapeutic roles? Baillières’s Clinical Gastroenterology 7: 95–128, 1993

    CAS  Google Scholar 

  • Axelson J, Hakanson R, Rosengren E, Sundler F. Hypergastrinaemia induced by acid blockade evokes enterochromaffin-like (ECL) cell hyperplasia in chicken, hamster and guinea-pig stomach. Cell and Tissue Research 254: 511–516, 1988

    PubMed  CAS  Google Scholar 

  • Bank S, Greenberg R, Blumstein M, Magier D, Schulman N, et al. ’spaced’ omeprazole dosing in maintenance therapy of H2RA resistant reflux esophagitis — results from 6 to 48 months. Abstract. Gastroenterology 104: A38, 1993

    Google Scholar 

  • Bardhan KD, Morris P, Thompson M, Dhande DS, Hinchliffe RFC, et al. Omeprazole in the treatment of erosive oesophagitis refractory to high dose Cimetidine and ranitidine. Gut 31: 745–749, 1990

    PubMed  CAS  Google Scholar 

  • Bayerdörffer E, Mannes GA, Sommer A, Höchter W, Weingart I, et al. High dose omeprazole treatment combined with amoxicillin eradicates Helicobacter pylori. European Journal of Gastroenterolgy and Hepatology 4: 697–702, 1992

    Google Scholar 

  • Beauchamp RD, Townsend CM, Singh P, Glass EJ, Thompson JC. Proglumide, a gastrin receptor antagonist, inhibits growth of colon cancer and enhances survival in mice. Annals of Surgery 202: 303–309, 1985

    PubMed  CAS  Google Scholar 

  • Belaiche J, Cattan D, Zittoun J, Marquet J, Yvart J. Effect of ranitidine on cobalamin absorption. Digestive Diseases and Sciences 28: 667–668, 1983

    PubMed  CAS  Google Scholar 

  • Bianchi Porro G, Boiling E, Barbara L, Blasi A, Capurso L, et al. Maintenance treatment with omeprazole in the prevention of duodenal ulcer relapse: a double-blind comparative trial. Abstract. Gastroenterology 98: A21, 1990

    Google Scholar 

  • Blum AL. Treatment of acid related disorders with gastric acid inhibitors: the state of the art. Digestion 47(Suppl. 1): 3–10, 1990

    PubMed  Google Scholar 

  • Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 88: 638–648, 1985

    PubMed  CAS  Google Scholar 

  • Borch K. Epidemiologic, clinicopathologic, and economic aspects of gastroscope screening of patients with pernicious anemia. Scandinavian Journal of Gastroenterology 21: 21–30, 1986

    PubMed  CAS  Google Scholar 

  • Borch K, Renvall H, Liedberg G, Andersen BN. Relations between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa. Scandinavian Journal of Gastroenterology 21: 357–363, 1986

    PubMed  CAS  Google Scholar 

  • Brinton LA, Gridley G, Hrubec Z, Hoover R, Fraumeni JF. Cancer risk following pernicious anaemia. British Journal of Cancer 59: 810–813, 1989

    PubMed  CAS  Google Scholar 

  • Brunner G, Creutzfeldt W, Harke U, Lamberts R. Efficacy and safety of long term treatment with omeprazole in patients with acid related diseases resistant to ranitidine. Canadian Journal of Gastroenterology 3(Suppl. A): 72A–76A, 1989

    Google Scholar 

  • Brunner GHG, Thiesemann C. The potential clinical role of intravenous omeprazole. Digestion 51(Suppl. 1): 17–20, 1992

    PubMed  Google Scholar 

  • Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? Gastroenterology 99: 345–351, 1990

    PubMed  CAS  Google Scholar 

  • Burlinson B, Morriss SH, Gatehouse DG, Tweats DJ. Genotoxicity studies of gastric acid inhibiting drugs. Lancet 335: 419–420, 1990

    PubMed  CAS  Google Scholar 

  • Carter DC. Cancer after peptic ulcer surgery. Gut 28: 921–923, 1987

    PubMed  CAS  Google Scholar 

  • Caygill CPJ, Hill MJ. Malignancy following surgery for benign peptic disease: a review. Italian Journal of Gastroenterology 24: 218–224, 1992

    PubMed  CAS  Google Scholar 

  • Cederberg C, Andersson T, Skanberg I. Omeprazole: pharmacokinetics and metabolism in man. Scandinavian Journal of Gastroenterology 166(Suppl.): 33–40, 1989

    CAS  Google Scholar 

  • Caygill CPJ, Hill MJ, Hall CN, Kirkham JS, Northfield TC. Increased risk of cancer at multiple site after gastric surgery for peptic ulcer. Gut 28: 924–928, 1987

    PubMed  CAS  Google Scholar 

  • Caygill CPJ, Hill MJ, Kirkham JS, Northfield TC. Mortality from gastric cancer following gastric surgery for peptic ulcer. Lancet 1: 929–931, 1986

    PubMed  CAS  Google Scholar 

  • Cederberg C, Thomson ABR, Mahachai V, Westin JA, Kirdeikis P, et al. Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology 103: 913–918, 1992

    PubMed  CAS  Google Scholar 

  • Colin-Jones DG, Langman MJS, Lawson DH, Logan RFA, Patterson KR, et al. Post-marketing surveillance of the safety of Cimetidine for up to ten years; incidence of carcinoma of the stomach and oesophagus. Quarterly Journal of Medicine 78: 13–19, 1991

    PubMed  CAS  Google Scholar 

  • Creutzfeldt W. The achlorhydria-carcinoid sequence: role of gastrin. Digestion 39: 61–79, 1988

    PubMed  CAS  Google Scholar 

  • Creutzfeldt W, Lamberts R. Is hypergastrinaemia dangerous to man? Scandinavian Journal of Gastroenterology 26(Suppl. 180): 179–191, 1991

    Google Scholar 

  • Creutzfeldt W, Lamberts R. Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth. Digestion 51(Suppl. 1): 76–81, 1992

    PubMed  Google Scholar 

  • Creutzfeldt W, Solcia E. Are diffuse gastric carcinomas neuroendocrine tumours ECL-omas? European Journal of Gastroenterology and Hepatology 3: 179–191, 1991

    Google Scholar 

  • Creutzfeldt W, Stöckmann F, Conlon JM, Fölsch UR, Bonatz G, et al. Effect of short- and long-term feeding of omeprazole in rat gastric endocrine cells. Digestion 35(Suppl. 1): 84–97, 1986

    PubMed  CAS  Google Scholar 

  • Daneshmend TK, Hawkey CJ, Langman MJS, Logan RFA, Long RG, et al. Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. British Medical Journal 304: 143–147, 1992

    PubMed  CAS  Google Scholar 

  • Dent J. Australian clinical trials of omeprazole in the management of reflux oesophagitis. Digestion 47(Suppl. 1): 69–71, 1990

    PubMed  Google Scholar 

  • Diaz D, Fabre I, Daujat M, Aubert BS, Bories P, et al. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 99: 131–747, 1990

    Google Scholar 

  • Elsborg L, Mosbech J. Pernicious anaemia as a risk factor in gastric cancer. Acta Medica Scandinavica 206: 315–318, 1979

    PubMed  CAS  Google Scholar 

  • Festen H, Klinkenberg-Knol E, Kuipers E, Lamers C, Jansen J, et al. Cobalamin absorption during omeprazole treatment: short and long-term studies. Abstract. Gastroenterology 104: A77, 1993

    Google Scholar 

  • Freston JW. Clinical significance of hypergstrinaemia: relevance to gastrin monitoring during omeprazole therapy. Digestion 51(Suppl. 1): 102–114, 1992

    PubMed  Google Scholar 

  • Fryklund J, Falknäs AK, Heiander HF. Omeprazole does not cause unscheduled DNA synthesis in rabbit parietal cells in vitro. Scandinavian Journal of Gastroenterology 27: 521–528, 1992

    PubMed  CAS  Google Scholar 

  • Furihata C, Hirose K, Matsushima T. Genotoxicity and cell proliferative activity of omeprazole in rat stomach mucosa. Mutation Research 262: 73–76, 1991

    PubMed  CAS  Google Scholar 

  • Goggins MG, Os’Brion S, Kelleher B, Scott JM, Weir DG. Omeprazole causes malabsorption of protein-bound cobalamin. Abstract. Gastroenterology 104: A88, 1993

    Google Scholar 

  • Graffner H, Singh G, Chaudry I, Milson JW. Omeprazole-induced hypergastrinemia does not influence growth of colon carcinoma. Digestive Diseases and Sciences 37: 485–489, 1992

    PubMed  CAS  Google Scholar 

  • Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 89: 1235–1241, 1985

    PubMed  CAS  Google Scholar 

  • Hakanson R, Blom H, Carlsson E, Larsson H, Ryberg B, et al. Hypergastrinaemia produces trophic effects in stomach but not in pancreas and intestines. Regulatory Peptides 13: 223–233, 1986a

    Google Scholar 

  • Hakanson R, Böttcher G, Sundler F, Vallgren S. Activation and hyperplasia of gastrin and enterochromaffin-like cells in the stomach. Digestion 35(Suppl. 1): 23–41, 1986b

    PubMed  Google Scholar 

  • Hall CN, Darkin D, Brimblecombe R, Cook AJ, Kirkham JS, et al. Evaluation of the nitrosamine hypothesis of gastric carcinogenesis in precancerous conditions. Gut 27: 491–498, 1986

    PubMed  CAS  Google Scholar 

  • Hall CN, Kirkham JS, Northfield TC. Urinary N-nitroso-proline excretion: a further evaluation of the nitrosamine hypothesis of gastric carcinogenesis in precancerous conditions. Gut 28: 216–220, 1987

    PubMed  CAS  Google Scholar 

  • Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 35(Suppl. 1): 42–55, 1986

    PubMed  Google Scholar 

  • Havu N, Mattsson H, Ekman L, Carlsson E. ECL-cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion 45: 189–195, 1990

    PubMed  CAS  Google Scholar 

  • Havu N, Maaroos HI, Sipponen P. Argyrophil cell hyperplasia associated with chronic corpus gastritis in gastric ulcer disease. Scandinavian Journal of Gastroenterology 26(Suppl. 186): 90–94, 1991

    Google Scholar 

  • Heatley RV, Sobala GM. Acid suppression and the gastric flora. Baillières’s Clinical Gastroenterology 7: 167–181, 1993

    CAS  Google Scholar 

  • Helander HF, Keeling DJ. Cell biology of gastric acid secretion. Baillières’s Clinical Gastroenterology 7: 1–21, 1993

    CAS  Google Scholar 

  • Holt S, Howden CW. Omeprazole - overview and opinion. Digestive Diseases and Sciences 36: 385–393, 1991a

    PubMed  CAS  Google Scholar 

  • Holt S, Powers RE, Howden CW. Antisecretory therapy and genotoxicity. Digestive Diseases and Sciences 36: 545–547, 1991b

    PubMed  CAS  Google Scholar 

  • Holt S, Zhao-Hua Z, Powers RE. Observations on a proposed measure of genotoxicity in rat gastric mucosa. Gastroenterology 101: 650–656, 1991c

    PubMed  CAS  Google Scholar 

  • Holtmann G, Armstrong D, Pöppin E, Bauerfeind A, Goebell H, et al. Influence of stress on the healing and relapse of duodenal ulcers. A prospective randomized study in 2109 patients with recurrent duodenal ulceration treated with ranitidine. Scandinavian Journal of Gastroenterology 27: 917–923, 1992

    PubMed  CAS  Google Scholar 

  • Hoosein NM, Kiener PA, Curry RC, Brattain MG. Evidence for autocrine growth stimulation of cultured colon tumor cells by a gastrin/cholecystokinin-like peptide. Experimental Cell Research 186: 15–21, 1990

    PubMed  CAS  Google Scholar 

  • Hoosein NM, Kiener PA, Curry RC, Rovati LC, McGilbra DK, et al. Antiproliferative effects of gastrin receptor antagonists and antibodies to gastrin on human colon carcinoma cell lines. Cancer Research 48: 7179–7183, 1988

    PubMed  CAS  Google Scholar 

  • Houghton PWJ, Leach S, Owen RW, Mortensen NJM, Hill MJ, et al. Use of a modified N-nitrosoproline test to show intragastric nitrosation in patients at risk of gastric cancer. British Journal of Cancer 60: 231–234, 1989

    PubMed  CAS  Google Scholar 

  • Howden CW. Clinical pharmacology of omeprazole. Clinical Pharmacokinetics 20: 38–49, 1991

    PubMed  CAS  Google Scholar 

  • Hui WM, Lam SK, Ho J, Lai CL, Lok ASF, et al. Effect of omeprazole on duodenal ulcer-associated antral gastritis and helicobacter pylori. Digestive Diseases and Sciences 36: 577–582, 1991

    PubMed  CAS  Google Scholar 

  • Humphries TJ. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Digestive Diseases and Sciences 36: 1665–1669, 1991

    PubMed  CAS  Google Scholar 

  • Im WB, Blakeman DP, Davis JP. Irreversible inactivation of rat gastric (H+K+)ATPase in vivo by omeprazole. Biochemical and Biophysical Research Communications 126: 78–82, 1985

    PubMed  CAS  Google Scholar 

  • Isal JP, Zeitoun P, Barbier P, Cayphas JP, Carlsson R. Comparison of two dosage regimens of omeprazole — 10 mg once daily and 20 mg weekends — as prophylaxis against recurrence of reflux esophagitis. Abstract. Gastroenterology 98 (Suppl.): A63, 1990

    Google Scholar 

  • Jansen JBMJ, Klinkenberg-Knol EC, Meuwissen SGM, De Bruijne JW, Festen HPM, et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 99: 621–628, 1990

    PubMed  CAS  Google Scholar 

  • Joelson S, Joelson IB, Lundborg P, Walan A, Wallander MA. Safety experience from long-term treatment with omeprazole. Digestion 51(Suppl. 1): 93–101, 1992

    PubMed  Google Scholar 

  • Johnson LR. Gastrointestinal hormones and their functions. Annual Review of Physiology 39: 135–158, 1977

    PubMed  CAS  Google Scholar 

  • Johnson LR. Regulation of gastrointestinal mucosal growth. Journal of Surgery 3: 477–487, 1979

    CAS  Google Scholar 

  • Kaufmann HP, Ottenjann R. Serum-Nüchtern-Gastrin-Werte bei Kolonadenomen und kolorektalen Karzinomen. Zeitschrift für Gastroenterologie 29: 527–528, 1991

    PubMed  CAS  Google Scholar 

  • Klinkenberg-Knol EC, Jansen JBMJ, Lamers CBHW, Nelis F, Meuwissen SGM. Temporary cessation of long-term maintance treatment with omeprazole in patients with H2-receptor-antagonist-resistant reflux oesophagitis. Effects on symptoms, endoscopy, serum gastrin, and gastric acid output. Scandinavian Journal of Gastroenterology 25: 1144–1150, 1990

    PubMed  CAS  Google Scholar 

  • Klinkenberg-Knol EC, Meuwissen SGM. Medical therapy of patients with reflux oesophagitis poorly responsive to H2-receptor antagonist therapy. Digestion 51(Suppl. 1): 44–48, 1992

    PubMed  Google Scholar 

  • Koop H. Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Alimentary Pharmacology and Therapeutics 6: 399–406, 1992

    PubMed  CAS  Google Scholar 

  • Koop H, Arnold R. Long-term maintenance treatment of reflux esophagitis with omeprazole. Digestive Diseases and Sciences 36: 552–557, 1991

    PubMed  CAS  Google Scholar 

  • Koop H, Bachern MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. Journal of Clinical Gastroenterology 14: 288–292, 1992

    PubMed  CAS  Google Scholar 

  • Koop H, Frank M, Kuly S, Nold R, Eissele R, et al. Gastric argyrophil (enterochromaffin-like), gastrin, and somatostatin cells after proximal selective vagotomy in man. Digestive Diseases and Sciences 38: 295–302, 1993

    PubMed  CAS  Google Scholar 

  • Koop H, Naumann-Koch CH, Arnold R. Effect of omeprazole on serum gastrin levels: influence of age and sex. Zeitschrift für Gastroenterologie 28: 603–605, 1990

    PubMed  CAS  Google Scholar 

  • Labenz J, Gyenes E, Rühl GH, Börsch G. Amoxicillin plus omeprazole versus triple therapy for eradication of helicobacter pylori in duodenal ulcer relapse: a prospective, randomized, and controlled study. Gut 34: 1167–1170, 1993

    PubMed  CAS  Google Scholar 

  • Labenz J, Gyenes E, Rühl GH, Börsch G. Two weeks treatment with amoxicillin/omeprazole for eradication of Helicobacter pylori. Zeitschrit für Gastroenterologie 30: 776–778, 1992

    CAS  Google Scholar 

  • Lamberts R, Creutzfeldt W, Stöckmann F, Jacubaschke U, Maas S, et al. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 39: 126–135, 1988

    PubMed  CAS  Google Scholar 

  • Lamberts R, Creutzfeldt W, Strüber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth and gastritis. Gastroenterology 104: 1356–1370, 1993

    PubMed  CAS  Google Scholar 

  • Langman MJS. Postmarketing surveillance and the examination of the long-term safety of antiulcer drugs. Baillières’s Clinical Gastroenterology 7: 183–190, 1993

    CAS  Google Scholar 

  • Lanzon-Miller S, Pounder RE, Hamilton MR, Ball S, Chronos NAF, et al. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Alimentary Pharmacology and Therapeutics 1: 239–251, 1987

    PubMed  CAS  Google Scholar 

  • Larsson H, Carlsson E, Mattsson H, Lundell L, Sundler F, et al. Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 90: 391–399, 1986

    PubMed  CAS  Google Scholar 

  • Lauritsen K, Andersen BN, Laursen LS, Hansen J, Havelund T, et al. Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Gastroenterology 100: 663–669, 1991

    PubMed  CAS  Google Scholar 

  • Lauritsen K, Rutgersson K, Boiling E, Brunner G, Eriksson S, et al. Omeprazole or ranitidine in duodenal ulcer prevention? Double-blind comparative trial. Abstract. Gastroenterology 104: A130, 1993

    Google Scholar 

  • Lechago J, Correa P. Prolonged achlorhydria and gastric neoplasia: is there a causal relationship? Gastroenterology 104: 1554–1557, 1993

    PubMed  CAS  Google Scholar 

  • Lee AK, DeLellis RA, Blount M, Nunnemacher G, Wolfe HJ. Pituitary proliferative lesions in aging male long-evans rats. A model of mixed multiple endocrine neoplasia syndrome. Laboratory Investigation 47: 595–602, 1982

    PubMed  CAS  Google Scholar 

  • Lehy T, Mignon M, Cadiot G, Elouaer-Blanc L, Ruszniewski P, et al. Gastric endocrine cell behavior in Zollinger-Ellison patients upon long-term potent antisecretory treatment. Gastroenterology 96: 1029–1040, 1989

    PubMed  CAS  Google Scholar 

  • Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 24: 270–276, 1983

    PubMed  CAS  Google Scholar 

  • Lind T, Cederberg C, Forssell H, Olausson M, Olbe L. Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment. Scandinavian Journal of Gastroenterology 23: 1259–1266, 1988

    PubMed  CAS  Google Scholar 

  • Lind T, Cederberg C, Olausson N, Olbe L. 24-hour intragastric acidity and plasma gastrin after omeprazole treatment and after proximal gastric vagotomy in duodenal ulcer patients. Gastroenterology 99: 1593–1598, 1990

    PubMed  CAS  Google Scholar 

  • Logan RPH, Gummett PA, Hegarty BT, Walker BMM, Baron JH, et al. Clarithromycin and omeprazole for Helicobacter pylori. Lancet 340: 239, 1992

    PubMed  CAS  Google Scholar 

  • Lorentzon P, Jackson R, Wallmark B, Sachs G. Inhibition of H+,K+-ATPase by omeprazole in isolated gastric vesicles requires proton transport. Biochimica et Biophysica Acta 897: 41–51, 1987

    PubMed  CAS  Google Scholar 

  • Lundell L, Backman L, Ekström P, Enander L-K, Falkmer S, et al. Prevention of relapse of reflux esophagitis after endoscopic healing: efficacy and safety of omeprazole compared with ranitidine. Scandinavian Journal of Gastroenterology 26: 248–256, 1991

    PubMed  CAS  Google Scholar 

  • Maaroos HI, Salupere V, Uibo R, Kekki M, Sipponen P. Seven-year follow-up study of chronic gastritis in gastric ulcer patients. Scandinavian Journal of Gastroenterology 20: 198–204, 1985

    PubMed  CAS  Google Scholar 

  • Marshall BJ. Campylobacter pylori: its link to gastritis and peptic ulcer disease. Reviews of Infectious Diseases 12(Suppl. 1): 587–593, 1990

    Google Scholar 

  • Maton PN. Omeprazole. New England Journal of Medicine 324: 965–975, 1991

    PubMed  CAS  Google Scholar 

  • Maton PN, Lack EE, Collen MJ, Cornelius MJ, David E, et al. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology 99: 943–950, 1990

    PubMed  CAS  Google Scholar 

  • Maton PN, Vinayek R, Frucht H, McArthur KA, Miller LS, et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 97: 827–836, 1989

    PubMed  CAS  Google Scholar 

  • Mattson H, Havu N, Bräutigam J, Carlsson K, Lundell L, et al. Partial corpectomy results in hypergastrinaemia and development of gastric ECL cell carcinoids in the rat. Gastroenterology 100: 311–319, 1991

    Google Scholar 

  • Möller H, Toftgaard C. Cancer occurrence in a cohort of patients surgically treated for peptic ulcer. Gut 32: 740–744, 1991

    PubMed  Google Scholar 

  • Möller H, Lindvig K, Lefter R, Mosbech J, Moller Jensen O. Cancer occurrence in a cohort of patients treated with Cimetidine. Gut 30: 1558–1562, 1989

    PubMed  Google Scholar 

  • Morris DL, Watson SA, Durrant LG, Harrison JD. Hormonal control of gastric and colorectal cancer in man. Gut 30: 425–429, 1989

    PubMed  CAS  Google Scholar 

  • Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. New England Journal of Medicine 325: 1132–1136, 1991

    PubMed  CAS  Google Scholar 

  • Oscarson J, Hakanson R, Liedberg G, Lundqvist G, Sundler F, et al. Variated serum gastrin concentration: trophic effects on the gastrointestinal tract of the rat. Acta Physiologica Scandinavica 475: 2–27, 1979

    CAS  Google Scholar 

  • Parkinson A, Hurwitz A. Omeprazole and the induction of human cytochrome P-450: a response to concern about potential adverse effects. Gastroenterology 100: 1157–1164, 1991

    PubMed  CAS  Google Scholar 

  • Parsonnet JP, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, et al. Helicobacter pylroi infection and the risk of gastric carcinoma. New England Journal of Medicine 325: 1127–1131, 1991

    PubMed  CAS  Google Scholar 

  • Penman ID, El-Omar E, McGregor JR, Hillan KJ, Os’Dwyer PJ, et al. Omeprazole inhibits colorectal carcinogenesis induced by azoxymethane in rats. Gut 34: 1559–1565, 1993

    PubMed  CAS  Google Scholar 

  • Penston J, Wormsley KG. Achlorhydria: hypergastrinaemia: carcinoids - a flawed hypothesis. Gut 28: 488–505, 1987

    PubMed  CAS  Google Scholar 

  • Poynter D, Pick CR, Harcourt RA, Selway SAM, Ainge G, et al. Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat. Gut 26: 1284–1295, 1985

    PubMed  CAS  Google Scholar 

  • Poynter D, Selway SAM. Neuroendocrine cell hyperplasia and neuroendocrine carcinoma of the rodent fundic stomach. Mutation Research 248: 303–319, 1991

    PubMed  CAS  Google Scholar 

  • Prichard PJ, Yeomans ND, Mihaly GW, Jones DB, Buckle PJ, et al. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 88: 64–69, 1985

    PubMed  CAS  Google Scholar 

  • Regardh CG. Pharmacokinetics and metabolism of omeprazole in man. Scandinavian Journal of Gastroenterology 21(Suppl. 118): 99–104, 1986

    Google Scholar 

  • Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 104: 994–1006, 1993

    PubMed  CAS  Google Scholar 

  • Rost KL, Brösicke H, Brockmöller J, Scheffler M, Helge H, et al. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clinical Pharmacology and Therapeutics 52: 170–180, 1992

    PubMed  CAS  Google Scholar 

  • Ryberg B, Axelson J, Hakanson R, Sundler F, Mattsson H. Trophic effects of continuous infusion of [Leu15-gastrin-17 in the rat. Gastroenterology 98: 33–38, 1990

    PubMed  CAS  Google Scholar 

  • Sachs G, Munson K, Hall K, Hersey SJ. Gastric H+,K+-ATPase as a therapeutic target in peptic ulcer disease. Digestive Diseases and Sciences 35: 1537–1544, 1990

    PubMed  CAS  Google Scholar 

  • Scott D, Reuben M, Zampighi G, Sachs G. Cell isolation and genotoxicity assessment in gastric mucosa. Digestive Diseases and Sciences 35: 1217–1225, 1990

    PubMed  CAS  Google Scholar 

  • Seitz JF, Giovannini M, Gouvernet J, Gauthier AP. Elevated serum gastrin levels in patients with colorectal neoplasia. Journal of Clinical Gastroenterology 13: 541–545, 1991

    PubMed  CAS  Google Scholar 

  • Shamburek RD, Schubert ML. Pharmacology of gastric acid inhibition. Baillières’s Clinical Gastroenterology 7: 23–54, 1993

    CAS  Google Scholar 

  • Shull GE. cDNA cloning of the β-subunit of the rat gastric H,K-ATPase. Journal of Biological Chemistry 265: 12 123–126, 1990

    Google Scholar 

  • Singh P, Townsend CM, Thompson JC, Narayan S, Guo YS. Gut hormones in colon cancer: past and prospective studies. Cancer Journal 3: 28–33, 1990

    CAS  Google Scholar 

  • Siurala M, Lehtola J, Ihamäki T. Atrophic gastritis and its sequelae. Results of 19–23 yearss’ follow-up examinations. Scandinavian Journal of Gastroenterology 9: 441–446, 1974

    PubMed  CAS  Google Scholar 

  • Smith JP, Kramer ST, Demers LM. Effects of gastrin and difluoromethylornithine on growth of human colon cancer. Digestive Diseases and Sciences 38: 520–528, 1993

    PubMed  CAS  Google Scholar 

  • Smith JP, Wood JG, Solomon TE. Elevated gastrin levels in patients with colon cancer or adenomatous polyps. Digestive Diseases and Sciences 34: 171–174, 1989

    PubMed  CAS  Google Scholar 

  • Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, et al. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4s’-hydroxylation recruited from an oriental population. Journal of Pharmacology and Experimental Therapeutics 262: 1195–1202, 1992

    PubMed  CAS  Google Scholar 

  • Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 41: 185–200, 1988

    PubMed  CAS  Google Scholar 

  • Solcia E, Capella C, Fiocca R, Rindi G, Rosai J. Gastric argyrophil carcinoidosis in patients with Zollinger Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. American Journal of Surgical Pathology 14: 503–513, 1990

    PubMed  CAS  Google Scholar 

  • Solcia E, Fiocca R, Havu N, Dalväg A, Carlsson R. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 51(Suppl. 1): 82–92, 1992

    PubMed  Google Scholar 

  • Solcia E, Fiocca R, Villani L, Gianatti A, Cornaggia M, et al. Morphology and pathogenesis of endocrine hyperplasias, precarcinoid lesions, and carcinoids arising in chronic atrophic gastritis. Scandinavian Journal of Gastroenterology 26(Suppl. 180): 146–159, 1991

    Google Scholar 

  • Soons PA, van den Berg G, Danhof M, van Brummelen P, Jansen JBMJ, et al. Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. European Journal of Clinical Pharmacology 42: 319–324, 1992

    PubMed  CAS  Google Scholar 

  • Spencer AJ, Bartolt TA, Henry DC, Eason CT, Sauerschell RJ, et al. Gastric morphological changes including carcinoid tumors in animals treated with a potent hypolipidemic agent, ciprofibrate. Toxicologie Pathology 17: 7–15, 1989

    CAS  Google Scholar 

  • Streeter AM, Duraiappah B, Boyle R, Os’Neill BJ, Pheils MT. Malabsorption of vitamin B12 after vagotomy. American Journal of Surgery 128: 340–343, 1974

    PubMed  CAS  Google Scholar 

  • Streeter AM, Goulston KJ, Bathur FA, Hilmer RS, Crane GG, et al. Cimetidine and malabsorption of cobalamin. Digestive Diseases and Sciences 27: 13–16, 1982

    PubMed  CAS  Google Scholar 

  • Sutfin T, Balmer K, Bostrom H, Eriksson S, Hoglund P, et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Therapeutic Drug Monitoring 11: 176–184, 1989

    PubMed  CAS  Google Scholar 

  • Suzuki H, Matsumoto K, Terashima H. Serum levels of gastrin in patients with colorectal neoplasia. Diseases of the Colon and Rectum 31: 716–717, 1988

    PubMed  CAS  Google Scholar 

  • Svendsen JH, Dahl C, Svendsen LB, Christiansen PM. Gastric cancer risk in achlorhydric patients. A long-term follow-up study. Scandinavian Journal of Gastroenterology 21: 16–20, 1986

    PubMed  CAS  Google Scholar 

  • Taburet AM, Geneve J, Bocquentin M, Simoneau G, Caulin C, et al. Theophylline steady state pharmacokinetics is not altered by omeprazole. European Journal of Clinical Pharmacology 42: 343–345, 1990

    Google Scholar 

  • Talley NJ, Chute CG, Larson DE, Epstein R, Lydick EG, et al. Risk of colorectal adenocarcinoma in pernicious anemia. Annals of Internal Medicine 111: 738–742, 1989

    PubMed  CAS  Google Scholar 

  • Tersmette AC, Offerhaus GJA, Giardiello FM, Brand R, Tersmette KWF, et al. Long-term prognosis after partial gastrectomy for benign conditions. Gastroenterology 101: 148–153, 1991

    PubMed  CAS  Google Scholar 

  • van Solinge WW, Nielsen FC, Friis-Hansen L, Falkmer UG, Rehfeld JF. Expression but incomplete maturation of progastrin in colorectal carcinomas. Gastroenterology 104: 1099–1107, 1993

    PubMed  Google Scholar 

  • Vecchia C, Negri E, Ds’Avanzo B, Franceschi S. Histamine-2-receptor antagonists and gastric cancer risk. Lancet 36: 355–357, 1990

    Google Scholar 

  • Walan A, Bader JP, Classen M, Lamers CBHW, Piper DW, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. New England Journal of Medicine 320: 69–75, 1989

    PubMed  CAS  Google Scholar 

  • Waldum HL, Haugen OA, Isaksen C, Mecsei R, Sandvik AK. Are diffuse gastric carcinomas neuroendocrine tumours (ECL-omas)? European Journal of Gastroenterology and Hepatology 3: 245–249, 1991

    Google Scholar 

  • Wong K, Beardshall K, Waters CM, Calam J, Poston GJ. Postprandial hypergastrinaemia in patients with colorectal cancer. Gut 32: 1352–1354, 1991

    PubMed  CAS  Google Scholar 

  • Wright NA, Goodlad RA. Omeprazole and genotoxicity. Lancet 335: 909–910, 1990

    Google Scholar 

  • Yapp R, Modlin IM, Kumar RR, Binder HJ, Dubrow R. Gastrin and colorectal cancer — evidence against an association. Digestive Diseases and Sciences 37: 481–484, 1992

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Georg-August-University, Göttingen, Germany

    Werner Creutzfeldt MD, FRCP

Authors
  1. Werner Creutzfeldt MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Creutzfeldt, W. Risk-Benefit Assessment of Omeprazole in the Treatment of Gastrointestinal Disorders. Drug-Safety 10, 66–82 (1994). https://doi.org/10.2165/00002018-199410010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199410010-00005

Keywords

Search

Navigation